Rocket Pharmaceuticals to Present at the Bank of America Securities 2022 Global Healthcare Conference
April 27 2022 - 7:00AM
Business Wire
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage
company advancing an integrated and sustainable pipeline of genetic
therapies for rare childhood disorders, today announces that
Kinnari Patel, Pharm.D., MBA, President and Chief Operating
Officer, will deliver an in-person company presentation at the Bank
of America Securities Healthcare Conference on Wednesday, May 11 at
2:20 p.m. ET at the Encore Hotel in Las Vegas.
About Rocket Pharmaceuticals, Inc. Rocket
Pharmaceuticals, Inc. (NASDAQ: RCKT) is advancing an integrated and
sustainable pipeline of genetic therapies that correct the root
cause of complex and rare childhood disorders. The Company’s
platform-agnostic approach enables it to design the best therapy
for each indication, creating potentially transformative options
for patients afflicted with rare genetic diseases. Rocket's
clinical programs using lentiviral vector (LVV)-based gene therapy
are for the treatment of Fanconi Anemia (FA), a difficult to treat
genetic disease that leads to bone marrow failure and potentially
cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric
genetic disorder that causes recurrent and life-threatening
infections which are frequently fatal, and Pyruvate Kinase
Deficiency (PKD), a rare, monogenic red blood cell disorder
resulting in increased red cell destruction and mild to
life-threatening anemia. Rocket’s first clinical program using
adeno-associated virus (AAV)-based gene therapy is for Danon
Disease, a devastating, pediatric heart failure condition. For more
information about Rocket, please visit www.rocketpharma.com.
Rocket Cautionary Statement Regarding Forward-Looking
Statements Various statements in this release concerning
Rocket’s future expectations, plans and prospects, including
without limitation, Rocket’s expectations regarding its guidance
for 2022 in light of COVID-19, the safety and effectiveness of
product candidates that Rocket is developing to treat Fanconi
Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate
Kinase Deficiency (PKD), and Danon Disease, the expected timing and
data readouts of Rocket’s ongoing and planned clinical trials,
Rocket’s plans for the advancement of its Danon Disease program
following the lifting of the FDA’s clinical hold and the safety,
effectiveness and timing of related pre-clinical studies and
clinical trials, may constitute forward-looking statements for the
purposes of the safe harbor provisions under the Private Securities
Litigation Reform Act of 1995 and other federal securities laws and
are subject to substantial risks, uncertainties and assumptions.
You should not place reliance on these forward-looking statements,
which often include words such as "believe," "expect,"
"anticipate," "intend," "plan," "will give," "estimate," "seek,"
"will," "may," "suggest" or similar terms, variations of such terms
or the negative of those terms. Although Rocket believes that the
expectations reflected in the forward-looking statements are
reasonable, Rocket cannot guarantee such outcomes. Actual results
may differ materially from those indicated by these forward-looking
statements as a result of various important factors, including,
without limitation, Rocket’s ability to monitor the impact of
COVID-19 on its business operations and take steps to ensure the
safety of patients, families and employees, the interest from
patients and families for participation in each of Rocket’s ongoing
trials, our expectations regarding the delays and impact of
COVID-19 on clinical sites, patient enrollment, trial timelines and
data readouts, our expectations regarding our drug supply for our
ongoing and anticipated trials, actions of regulatory agencies,
which may affect the initiation, timing and progress of
pre-clinical studies and clinical trials of its product candidates,
Rocket’s dependence on third parties for development, manufacture,
marketing, sales and distribution of product candidates, the
outcome of litigation, and unexpected expenditures, as well as
those risks more fully discussed in the section entitled "Risk
Factors" in Rocket’s Annual Report on Form 10-K for the year ended
December 31, 2020, filed March 1, 2021 with the SEC. Accordingly,
you should not place undue reliance on these forward-looking
statements. All such statements speak only as of the date made, and
Rocket undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220427005195/en/
Media Kevin Giordano Director, Corporate Communications
kgiordano@rocketpharma.com
Investors Jessie Yeung, M.B.A. Vice President, Investor
Relations and Corporate Finance investors@rocketpharma.com
Rocket Pharmaceuticals (NASDAQ:RCKT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rocket Pharmaceuticals (NASDAQ:RCKT)
Historical Stock Chart
From Apr 2023 to Apr 2024